Beam Therapeutics Inc. Equity-NMS: BEAM

$- -16.42 (January 1, 1970)

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.
Powered by Vested Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly
Loading, Please wait...
Previous close :$16.42
Open :$15.83
Today's high :$16.66
Today's low :$14.72
52W low :$14.72
52W high :$35.25
EPS(TTM): :-4.58
Shares O/S :99.84 M
Market cap :1.54 B

Compare with Other Stocks

Stocks Price 1D PE Market Cap
Beam Therapeutics Inc. $- -0.11% - 1.54B

Frequently Asked Questions

What is the share price of Beam Therapeutics Inc. today?

Beam Therapeutics Inc. (BEAM) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

About Beam Therapeutics Inc.

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).